VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
QTEX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
QTEXQTREX Quantum Ltd.
$1.09$45M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksQTEXCash Flow

QTREX Quantum Ltd. (QTEX) Cash Flow Statement

8Y historyFree accessUpdated daily

Cash flow generation remains non-existent, with the company failing to produce positive free cash flow, leaving it entirely dependent on external financing to sustain its operations as evidenced by the $2.1 million cash balance.

Income StatementBalance SheetCash FlowRatios

QTEX Cash Flow Statement

Annual statement

QTEX Cash Flow Statement

QTREX Quantum Ltd. (QTEX) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations0-9.86M-9.37M-9.76M-7.38M-7.88M-1.88M-1.11M4.8K
Operating CF Margin %--3412.11%--157.76%----
Operating CF Growth %-100%-5.2%3.92%-32.2%6.31%-319.88%-68.86%-23245.83%-
Net Income-12.64M-13.22M-11.05M-11.29M-10.27M-16.95M-7.23M-4.58M-39.6K
Depreciation & Amortization0449K171K111K361K25K203K76K0
Stock-Based Compensation001.89M1.49M4.88M6.7M3.9M3.29M0
Deferred Taxes000000204K-3.29K0
Other Non-Cash Items03.13M48K-108K-3.05M2.58M701K12.29K0
Working Capital Changes0-219K-432K41K704K-233K348K84K44.4K
Change in Receivables000190K29K-468K10K-46K-3.6K
Change in Inventory0-291K-444K0-29K468K-10K46K0
Change in Payables0-105K-44K46K71K87K-70K72K0
Cash from Investing0565K1.49M4.59M-7.25M-246K-26K-71K0
Capital Expenditures0-103K-164K-206K-304K-176K-23K-31K0
CapEx % of Revenue0%35.64%---6.5%----
Acquisitions000000000
Investments---------
Other Investing001.65M4.8M175K-70K-3K-40K0
Cash from Financing07.33M7.9M3.45M-399K30.42M2.29M1.27M3.6K
Debt Issued (Net)0000-399K7.2M2.29M1.27M0
Equity Issued (Net)07.33M7.9M3.45M023M000
Dividends Paid000000000
Share Repurchases000000000
Other Financing004K3K0227K003.6K
Net Change in Cash-5.04M-1.94M71K-1.71M-16.97M23.25M400K88K9.6K
Free Cash Flow0-9.96M-9.54M-9.96M-7.68M-8.05M-1.9M-1.14M4.8K
FCF Margin %0%-3447.75%--164.26%----
FCF Growth %-100%-4.47%4.26%-29.65%4.58%-324.07%-66.29%-23891.67%-
FCF per Share0.00-0.34-0.52-0.82-0.71-1.52-0.26-0.080.00
FCF Conversion (FCF/Net Income)-0.00x0.75x848.10x0.86x1.84x0.46x0.26x0.24x-0.12x
Interest Paid0072K000000
Taxes Paid000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent capital dilution risk

Earnings Decoupled From Cash Reality

As reported in recent financial statements, IINN's operating cash flow has remained effectively at zero for the majority of the last ten quarters, highlighting a profound disconnect between accounting losses and the actual cash resources available to fund the company's ongoing clinical development and regulatory milestones.

The persistent gap between net income and operating cash flow suggests that the company is not generating any meaningful cash from its core operations. Investors should monitor this lack of conversion, as it indicates that the business model is currently entirely dependent on external financing rather than internal cash generation.

Free Cash Flow Remains Nonexistent

Based on the provided quarterly data, IINN has failed to establish a positive free cash flow trajectory, with nearly every period showing zero or negative cash generation, which underscores the company's status as a pre-commercial entity reliant on capital markets to sustain its research-heavy cost structure.

The absence of a positive FCF trend suggests that the company is in a deep investment phase where cash outflows are strictly tied to R&D and administrative overhead. This trajectory warrants caution, as there is no evidence of operational self-sufficiency emerging from the current clinical trial activities.

Capital Expenditure Remains Highly Sporadic

According to historical cash flow filings, IINN's capital expenditure has been largely dormant, with the exception of a $172,000 outlay in 2022Q4, suggesting that the firm has yet to commit to the significant infrastructure or manufacturing assets required for full-scale commercial production of its ART system.

The lack of consistent capital investment implies that the company is currently prioritizing clinical validation over the build-out of physical production capacity. Analysts should interpret this as a sign that the firm is deferring major capital commitments until regulatory hurdles are cleared and commercial demand is validated.

Capital Allocation Limited By Burn

As indicated by the company's financial records, capital deployment is currently non-existent regarding dividends or share repurchases, as the firm's primary focus remains the preservation of its limited cash reserves to fund the high-cost development of its proprietary respiratory technology and associated regulatory submissions.

The absence of capital return programs is expected for a firm in this stage of development, but it highlights the extreme pressure on management to allocate every dollar toward survival. Investors should monitor whether future capital raises are used for genuine commercial scaling or merely to cover the ongoing operational burn.

Cash Flow Statement Obscures Sustainability

Based on the provided data, the cash flow statement appears to obscure the true extent of the company's financial fragility by showing minimal activity, which may mask the underlying reality that the firm is rapidly depleting its cash reserves to fund its high-intensity R&D operations.

The lack of significant cash flow movement suggests that the company is operating in a 'maintenance mode' that does not reflect the high-stakes nature of its clinical development. This may indicate that the firm is managing its cash burn through extreme austerity, which could potentially jeopardize the speed and quality of its regulatory progress.

QTEX — Frequently Asked Questions

Quick answers to the most common questions about buying QTEX stock.

How much cash does QTREX Quantum Ltd. (QTEX) generate from operations?

QTREX Quantum Ltd. (QTEX) generated $-9.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is QTREX Quantum Ltd.'s free cash flow?

QTREX Quantum Ltd. (QTEX) reported negative free cash flow of $10.0M in 2025, indicating capital requirements exceeded cash from operations.

What is QTREX Quantum Ltd.'s capital expenditure (CapEx)?

QTREX Quantum Ltd. (QTEX) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.